Windlas Biotech Intrinsic Value
Windlas Biotech intrinsic value. Windlas Biotech (WINDLAS) median intrinsic value is ₹785.45 from 9 valuation models (range ₹305–₹1644), vs current price ₹1017.90 — -22.8% downside (Trading Above Calculated Value), margin of safety -29.6%. For current market price and key ratios, visit WINDLAS share price screener.
WINDLAS Valuation Methods Summary — DCF, Graham Number & P/E
Windlas Biotech intrinsic value across 9 models vs current price ₹1017.90 — upside/downside and value range per method. Read WINDLAS ex-dividend dates for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹746.24 | ₹596.99 - ₹895.49 | -26.7% | EPS: ₹33.92, Sector P/E: 22x |
| Book Value Method | asset | ₹920.00 | ₹828.00 - ₹1012.00 | -9.6% | Book Value/Share: ₹460.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1643.64 | ₹1479.28 - ₹1808.00 | +61.5% | Revenue/Share: ₹821.82, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1163.64 | ₹1047.28 - ₹1280.00 | +14.3% | EBITDA: ₹128.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹839.70 | ₹671.76 - ₹1007.64 | -17.5% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹305.37 | ₹274.83 - ₹335.91 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹524.06 | ₹471.65 - ₹576.47 | -48.5% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹785.45 | ₹706.91 - ₹864.00 | -22.8% | ROE: 14.2%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹592.51 | ₹533.26 - ₹651.76 | -41.8% | EPS: ₹33.92, BVPS: ₹460.00 |
WINDLAS Intrinsic Value vs Market Price — All Valuation Models
Windlas Biotech fair value range ₹305–₹1644 vs current market price ₹1017.90 across 9 valuation models. Compare with WINDLAS fundamental valuation to assess whether the stock is under or overvalued.
WINDLAS Intrinsic Value Analysis — Undervalued or Overvalued?
Windlas Biotech median intrinsic value ₹785.45, current price ₹1017.90 — Trading Above Calculated Value by 22.8%, margin of safety -29.6%.
What is the intrinsic value of WINDLAS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Windlas Biotech (WINDLAS) is ₹785.45 (median value). With the current market price of ₹1017.90, this represents a -22.8% variance from our estimated fair value.
The valuation range spans from ₹305.37 to ₹1643.64, indicating ₹305.37 - ₹1643.64.
Is WINDLAS undervalued or overvalued?
Based on our multi-method analysis, Windlas Biotech (WINDLAS) appears to be trading above calculated value by approximately 22.8%.
WINDLAS Financial Health — Key Ratios vs Industry Benchmarks
Windlas Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 105.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 14.2% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 13.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.19x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
WINDLAS Cash Flow Quality — Operating & Free Cash Flow
Windlas Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹68 Cr | ₹31 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹109 Cr | ₹63 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹61 Cr | ₹54 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹9 Cr | ₹-69 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹12 Cr | ₹2 Cr | Positive Free Cash Flow | 7/10 |